File downloaded on 2026-06-17
Source URL: https://medicines.health.europa.eu/veterinary/sl/700000131556

REFORDOG 100 mg/500 mg spot-on solution for dogs over 4 kg up to 10 kg

Ima dovoljenje za promet

- Imidacloprid
- Permethrin (40:60)

Informacije o zdravilu

Ime zdravila:
REFORDOG 100 mg/500 mg spot-on solution for dogs over 4 kg up to 10 kg

Učinkovina:
Na voljo samo v English
Na voljo samo v English

Ciljne živalske vrste:
Na voljo samo v Bulgarian Spanish Czech Danish German Estonian Greek English French Italian Latvian Lithuanian Hungarian Dutch Romanian Finnish Swedish Icelandic Norwegian

Pot uporabe:
Nanos na kožo

Podatki o zdravilu

Učinkovina / Jakost:

Na voljo samo v English
100.00 milligram(s) / 1.00 Pipeta

Na voljo samo v English
500.00 milligram(s) / 1.00 Pipeta

Farmacevtska oblika:

Kožni nanos, raztopina

Anatomsko-terapevtsko-kemična veterinarska oznaka klasifikacija zdravil, ki se uporabljajo v veterini (ATCvet):

QP53AC54

Pravni status za dobavo/izdajo zdravila:

Zdravilo, ki se izdaja brez veterinarskega recepta

Status dovoljenja za promet z zdravilom:

Valid

Ima dovoljenje za promet v:

Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian

---

Na voljo v:

Italy

Opis ovojnine zdravila:

Na voljo samo v English

Na voljo samo v English

Na voljo samo v English

Na voljo samo v English

Na voljo samo v English

Na voljo samo v English

Dodatne informacije

Vrsta dovoljenja:

Na voljo samo v English French Croatian Italian Latvian Finnish Swedish Icelandic Norwegian

---

Pravna podlaga za izdajo dovoljenja za promet z zdravilom:
Na voljo samo v English Italian Latvian Norwegian

Imetnik dovoljenja za promet z zdravilom:
Vetpharma Animal Health S.L.

Datum dovoljenja za promet z zdravilom:
10/01/2025

Proizvodna mesta, odgovorna za sproščanje serij:
Ab7 Sante

Pristojni organ:
European Medicines Agency

Številka dovoljenja za promet z zdravilom:
105649

Datum spremembe statusa dovoljenja za promet:
10/01/2025

Referenčna država članica:
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian

---

Številka postopka:
IE/V/0666/002

Zadevne države članice:
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian

Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Croatian Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Estonian English French Lithuanian Portuguese Swedish Icelandic Norwegian

---

Za poročila o domnevnih neželenih učinkih zdravil za uporabo v veterinaski medicini obiščite stran: www.adrreports.eu/vet

Dokumenti

Povzetek glavnih značilnosti zdravila

Ta dokument ne obstaja v tem jeziku (slovenščina). Lahko ga najdete spodaj v drugem jeziku.

Combined File of all Documents

Ta dokument ne obstaja v tem jeziku (slovenščina). Lahko ga najdete spodaj v drugem jeziku.

ie-puar-mr-iev0666002-refordog-100-mg500-mg-spot-on-solution-for-dogs-ov-en.pdf